Design Therapeutics, Inc.: DRIEHAUS CAPITAL MANAGEMENT LLC discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Driehaus Capital Management LLC disclosed a stake exceeding 5% in Design Therapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0000938206-26-000062). The passive-investment disclosure signals that Driehaus has crossed the 5% beneficial ownership threshold in the clinical-stage biotech. The exact share count and percentage were not specified in the filing headline. Investors will watch for further 13G/13D amendments to see whether Driehaus maintains or builds its position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Driehaus Capital Management LLC, Design Therapeutics, Inc.